Mental DailyMental Daily
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • My Bookmarks
Aa
Mental Daily
Aa
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • Opinion
Search
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • My Bookmarks
Follow US
  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store
© 2024 - Mental Daily. All Rights Reserved.
Clinical

ALS treatment riluzole may also aid in treating Alzheimer’s disease

Staff Writer
Staff Writer 4 years ago
Updated 2021/07/29 at 3:53 AM
Share
SHARE

The common use of drug treatment for ALS may also prove to be effective for slowing cognitive decline associated with Alzheimer’s disease, according to a study released in the journal Brain.

Known as riluzole, the treatment was examined among a number of participants. As part of a clinical trial, 50 participants in late adulthood had been administered either the drug or a placebo, twice a day for a span of six months.

Through its role in modulating the neurotransmitter glutamate, the drug treatment’s purported effects on slowing cerebral glucose metabolism decline in patients with Alzheimer’s was subsequently explored.

“A 6-month phase 2 double-blind, randomized, placebo-controlled study was conducted at two sites. Participants consisted of males and females, 50 to 95 years of age, with a clinical diagnosis of probable Alzheimer’s disease, and Mini-Mental State Examination between 19 and 27,” the study states.

“These findings support our main primary hypothesis that cerebral glucose metabolism would be better preserved in the riluzole treated group than in the placebo group and investigations in future larger and longer studies to test riluzole as a potential novel therapeutic intervention for Alzheimer’s disease.”

The study was funded by the Alzheimer’s Drug Discovery Foundation.

Photo: dreamstime

You Might Also Like

Study explores victim-blaming, manipulation, and denial as tactics used by terrorists

Study finds people change their mind about conspiracy theories but not often

Study finds majority of prisoners receive no visitors, possibly affecting recidivism

Dementia risk factors differ by ethnicity, according to new research

Researchers investigate how endocannabinoids regulate the brain’s stress response

TAGGED: riluzole, ALS, Alzheimer's disease, cognition
Staff Writer July 28, 2021
Share this Article
Facebook Twitter Whatsapp Whatsapp Email Print
Previous Article Study suggests a simple blood test can soon measure the circadian clock
Next Article A substantial amount of women planning a pregnancy are nicotine smokers

Recommended

Clinical

Study explores victim-blaming, manipulation, and denial as tactics used by terrorists

1 Min Read
Social

Study finds people change their mind about conspiracy theories but not often

2 Min Read
Clinical

Study finds majority of prisoners receive no visitors, possibly affecting recidivism

2 Min Read
Clinical

Dementia risk factors differ by ethnicity, according to new research

2 Min Read
//

We are a trusted online source for research news and resources on all aspects of the mind and human behavior.

Verticals

  • Clinical
  • Health
  • Social
  • I/O
  • Opinion

Social

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Links

  • About
  • Contact
  • The Editor
  • Terms & Conditions
  • Privacy Policy
  • Mental Health
Follow US

© 2024 Mental Daily. All Rights Reserved.

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?